PUBLISHER: Fortune Business Insights Pvt. Ltd. | PRODUCT CODE: 1930032
PUBLISHER: Fortune Business Insights Pvt. Ltd. | PRODUCT CODE: 1930032
Psoriasis Treatment Market Size, Share, Growth and Global Industry Analysis By Type & Application, Regional Insights and Forecast to 2025-2034
Growth Factors of psoriasis treatment Market
The global psoriasis treatment market size was valued at USD 29.15 billion in 2025 and is projected to grow to USD 31.42 billion in 2026, reaching USD 72.99 billion by 2034. Market growth is supported by rising disease prevalence, increasing adoption of biologic therapies, expanding awareness programs, and strong clinical development pipelines. In 2025, North America dominated the market with a share of 74.83%, driven by high biologic usage, extensive insurance coverage, and robust regulatory approvals.
Psoriasis is a chronic autoimmune inflammatory disorder characterized by rapid skin cell proliferation, plaque formation, inflammation, and joint involvement in psoriatic arthritis. Approximately 30%-40% of psoriasis patients develop psoriatic arthritis, increasing long-term therapy needs. Plaque psoriasis remains the most common form, accounting for 80%-90% of total cases, creating sustained demand for long-term pharmacologic management.
Market Drivers
The growing prevalence of psoriasis remains a primary driver. An estimated 2%-3% of the global population suffers from psoriasis, increasing demand for effective systemic and topical therapies. Governments and healthcare organizations are promoting early diagnosis and disease awareness, improving treatment initiation rates.
Another major driver is the strong pipeline of biologic drugs targeting inflammatory cytokines. Regulatory approvals for IL-17, IL-23, and TYK2 inhibitors are improving clinical outcomes and increasing physician confidence in biologic prescribing. Expanded indications for pediatric and psoriatic arthritis populations further increase patient eligibility.
Market Trends
A dominant trend is the shift toward biologic therapies that target specific immune pathways with improved safety and efficacy. Biologics offer higher clearance rates, longer remission periods, and reduced systemic toxicity compared to conventional therapies. Manufacturers are investing heavily in next-generation biologics and biosimilars to improve affordability and expand market access.
Teledermatology adoption is also improving patient monitoring and prescription continuity, particularly in rural regions and during public health emergencies, supporting long-term medication adherence.
Market Restraints
High treatment costs remain a significant barrier, especially in developing countries. Biologic therapies involve high manufacturing expenses, leading to elevated out-of-pocket costs for patients. Limited reimbursement frameworks restrict biologic adoption in low-income populations, delaying therapy initiation and reducing market penetration.
Topical and systemic alternatives remain cost-effective but often lack the long-term disease control achieved by biologics, creating access disparities across regions.
Segmentation Analysis
By Drug Class
The market is segmented into TNF inhibitors, interleukin inhibitors, and others. TNF inhibitors dominated with 41.31% market share in 2026, driven by long-established clinical usage and biosimilar availability. However, interleukin inhibitors are registering the fastest growth due to superior efficacy, improved safety profiles, and expanding clinical trial programs.
By Type
By type, the market includes plaque psoriasis, psoriatic arthritis, and others. Plaque psoriasis accounted for 41.31% market share in 2026, driven by high disease prevalence and large patient populations. Psoriatic arthritis is experiencing rapid growth due to improved diagnostic rates and expanded biologic indications.
By Product Type
Based on product type, the market is segmented into biologics and non-biologics. Biologics dominated with 90.73% share in 2026, reflecting strong adoption of targeted therapies such as IL-17 and IL-23 inhibitors. Non-biologics continue to grow due to oral drug approvals and lower cost accessibility.
By Route of Administration
The market is categorized into oral, parenteral/systemic, and topical. Parenteral/systemic therapies accounted for 83.48% share in 2026, supported by widespread biologic administration through injections and infusions. Oral therapies are expanding due to convenience and increasing TYK2 inhibitor approvals.
By Distribution Channel
Distribution includes hospital pharmacies, retail pharmacies, and online pharmacies. Retail pharmacies dominated in 2024 due to wide accessibility and refill convenience, while online pharmacies are expanding rapidly through home delivery services and biosimilar partnerships.
Regional Outlook
North America generated USD 21.81 billion in 2025, supported by advanced biologic adoption and strong reimbursement systems. The U.S. market reached USD 21.75 billion in 2026, driven by FDA approvals and Medicare pricing negotiations.
Europe holds strong demand, with Germany valued at USD 1.05 billion and the U.K. at USD 0.63 billion in 2026, supported by regulatory approvals and national healthcare coverage. Asia Pacific is the fastest-growing region, with China at USD 0.74 billion, Japan at USD 0.61 billion, and India at USD 0.27 billion in 2026, driven by clinical trial expansion and government awareness programs. Latin America and Middle East & Africa are growing through expanding healthcare access and disease awareness.
Competitive Landscape
Key players include AbbVie, Johnson & Johnson, Novartis, Pfizer, Eli Lilly, Amgen, LEO Pharma, UCB, and Sun Pharmaceutical Industries. Market leaders focus on biologic innovation, biosimilar expansion, and multi-indication labeling strategies. Strategic acquisitions and global clinical programs strengthen product pipelines and market coverage.
Report Coverage
The report analyzes market size and value for 2025, 2026, and 2034, with segmentation by drug class, type, product type, route of administration, and distribution channel. It includes regional and country-level market values, regulatory trends, product launches, clinical pipeline developments, and competitive strategies shaping the global psoriasis treatment industry.
Conclusion
The psoriasis treatment market is expanding from USD 29.15 billion in 2025 to USD 31.42 billion in 2026, reaching USD 72.99 billion by 2034, driven by rising disease burden, biologic therapy innovation, and expanding global treatment access. Dominance of biologics, strong performance of parenteral therapies, and leadership by North America reflect advanced treatment adoption, while rapid growth in Asia Pacific highlights increasing healthcare investment and regulatory support. Continued innovation in immune-targeted therapies, biosimilars, and oral treatment options is strengthening long-term market sustainability across diverse patient populations.
Segmentation By Drug Class
- TNF Inhibitors
- Interleukins Inhibitors
- Others
By Type
- Plaque Psoriasis
- Psoriatic Arthritis
- Others
By Product Type
- Biologics
- Non-Biologics
By Route of Administration
- Oral
- Parenteral/Systemic
- Topical
By Distribution Channel
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
By Region
- North America (By Drug Class, Type, Product Type, Route of Administration, Distribution Channel, and Country)
- U.S. (By Type)
- Canada (By Type)
- Europe (By Drug Class, Type, Product Type, Route of Administration, Distribution Channel, and Country/Sub-region)
- U.K. (By Type)
- Germany (By Type)
- France (By Type)
- Italy (By Type)
- Spain (By Type)
- Scandinavia (By Type)
- Rest of Europe (By Type)
- Asia Pacific (By Drug Class, Type, Product Type, Route of Administration, Distribution Channel, and Country/Sub-region)
- Japan (By Type)
- China (By Type)
- India (By Type)
- Australia & New Zealand (By Type)
- Rest of Asia Pacific (By Type)
- Latin America (By Drug Class, Type, Product Type, Route of Administration, Distribution Channel, and Country/Sub-region)
- Brazil (By Type)
- Mexico (By Type)
- Rest of Latin America (By Type)
- Middle East & Africa (By Drug Class, Type, Product Type, Route of Administration, Distribution Channel, and Country/Sub-region)
- GCC (By Type)
- South Africa (By Type)
- Rest of the Middle East & Africa (By Type)
Table of Content
1. Introduction
- 1.1. Market Scope
- 1.2. Market Segmentation
- 1.3. Market Methodology
- 1.4. Definitions and Assumptions
2. Executive Summary
3. Market Dynamics
- 3.1. Market Drivers
- 3.2. Market Restraints
- 3.3. Market Opportunities
- 3.4. Market Trends
4. Key Insights
- 4.1. Prevalence of Psoriasis, By Key Countries, 2025
- 4.2. Overview: Regulatory Scenario & Reimbursement Scenario, By Key Countries/Region
- 4.3. New Product Launches, By Key Players
- 4.4. Pipeline Analysis, By Key Players
- 4.5. Key Industry Developments, By Key Players
- 4.6. Impact of COVID-19 on the Market
5. Global Psoriasis Treatment Market Analysis, Insights and Forecast, 2021-2034
- 5.1. Market Analysis, Insights and Forecast - By Drug Class
- 5.1.1. TNF Inhibitors
- 5.1.2. Interleukins Inhibitors
- 5.1.3. Others
- 5.2. Market Analysis, Insights and Forecast - By Type
- 5.2.1. Plaque Psoriasis
- 5.2.2. Psoriatic Arthritis
- 5.2.3. Others
- 5.3. Market Analysis, Insights and Forecast - By Product Type
- 5.3.1. Biologics
- 5.3.2. Non-Biologics
- 5.4. Market Analysis, Insights and Forecast - By Route of Administration
- 5.4.1. Oral
- 5.4.2. Parenteral/Systemic
- 5.4.3. Topical
- 5.5. Market Analysis, Insights and Forecast - By Distribution Channel
- 5.5.1. Hospital Pharmacies
- 5.5.2. Retail Pharmacies
- 5.5.3. Online Pharmacies
- 5.6. Market Analysis, Insights and Forecast - By Region
- 5.6.1. North America
- 5.6.2. Europe
- 5.6.3. Asia Pacific
- 5.6.4. Latin America
- 5.6.5. Middle East & Africa
6. North America Psoriasis Treatment Market Analysis, Insights and Forecast, 2021-2034
- 6.1. Market Analysis, Insights and Forecast - By Drug Class
- 6.1.1. TNF Inhibitors
- 6.1.2. Interleukins Inhibitors
- 6.1.3. Others
- 6.2. Market Analysis, Insights and Forecast - By Type
- 6.2.1. Plaque Psoriasis
- 6.2.2. Psoriatic Arthritis
- 6.2.3. Others
- 6.3. Market Analysis, Insights and Forecast - By Product Type
- 6.3.1. Biologics
- 6.3.2. Non-Biologics
- 6.4. Market Analysis, Insights and Forecast - By Route of Administration
- 6.4.1. Oral
- 6.4.2. Parenteral/Systemic
- 6.4.3. Topical
- 6.5. Market Analysis, Insights and Forecast - By Distribution Channel
- 6.5.1. Hospital Pharmacies
- 6.5.2. Retail Pharmacies
- 6.5.3. Online Pharmacies
- 6.6. Market Analysis, Insights and Forecast - By Country
- 6.6.1. U.S.
- 6.6.1.1. By Type
- 6.6.2. Canada
- 6.6.2.1. By Type
- 6.6.1. U.S.
7. Europe Psoriasis Treatment Market Analysis, Insights and Forecast, 2021-2034
- 7.1. Market Analysis, Insights and Forecast - By Drug Class
- 7.1.1. TNF Inhibitors
- 7.1.2. Interleukins Inhibitors
- 7.1.3. Others
- 7.2. Market Analysis, Insights and Forecast - By Type
- 7.2.1. Plaque Psoriasis
- 7.2.2. Psoriatic Arthritis
- 7.2.3. Others
- 7.3. Market Analysis, Insights and Forecast - By Product Type
- 7.3.1. Biologics
- 7.3.2. Non-Biologics
- 7.4. Market Analysis, Insights and Forecast - By Route of Administration
- 7.4.1. Oral
- 7.4.2. Parenteral/Systemic
- 7.4.3. Topical
- 7.5. Market Analysis, Insights and Forecast - By Distribution Channel
- 7.5.1. Hospital Pharmacies
- 7.5.2. Retail Pharmacies
- 7.5.3. Online Pharmacies
- 7.6. Market Analysis, Insights and Forecast - By Country/Sub-region
- 7.6.1. U.K
- 7.6.1.1. By Type
- 7.6.2. Germany
- 7.6.2.1. By Type
- 7.6.3. France
- 7.6.3.1. By Type
- 7.6.4. Spain
- 7.6.4.1. By Type
- 7.6.5. Italy
- 7.6.5.1. By Type
- 7.6.6. Scandinavia
- 7.6.6.1. By Type
- 7.6.7. Rest of Europe
- 7.6.7.1. By Type
- 7.6.1. U.K
8. Asia Pacific Psoriasis Treatment Market Analysis, Insights and Forecast, 2021-2034
- 8.1. Market Analysis, Insights and Forecast - By Drug Class
- 8.1.1. TNF Inhibitors
- 8.1.2. Interleukins Inhibitors
- 8.1.3. Others
- 8.2. Market Analysis, Insights and Forecast - By Type
- 8.2.1. Plaque Psoriasis
- 8.2.2. Psoriatic Arthritis
- 8.2.3. Others
- 8.3. Market Analysis, Insights and Forecast - By Product Type
- 8.3.1. Biologics
- 8.3.2. Non-Biologics
- 8.4. Market Analysis, Insights and Forecast - By Route of Administration
- 8.4.1. Oral
- 8.4.2. Parenteral/Systemic
- 8.4.3. Topical
- 8.5. Market Analysis, Insights and Forecast - By Distribution Channel
- 8.5.1. Hospital Pharmacies
- 8.5.2. Retail Pharmacies
- 8.5.3. Online Pharmacies
- 8.6. Market Analysis, Insights and Forecast - By Country/Sub-region
- 8.6.1. Japan
- 8.6.1.1. By Type
- 8.6.2. China
- 8.6.2.1. By Type
- 8.6.3. India
- 8.6.3.1. By Type
- 8.6.4. Australia & New Zealand
- 8.6.4.1. By Type
- 8.6.5. Rest of Asia Pacific
- 8.6.5.1. By Type
- 8.6.1. Japan
9. Latin America Psoriasis Treatment Market Analysis, Insights and Forecast, 2021-2034
- 9.1. Market Analysis, Insights and Forecast - By Drug Class
- 9.1.1. TNF Inhibitors
- 9.1.2. Interleukins Inhibitors
- 9.1.3. Others
- 9.2. Market Analysis, Insights and Forecast - By Type
- 9.2.1. Plaque Psoriasis
- 9.2.2. Psoriatic Arthritis
- 9.2.3. Others
- 9.3. Market Analysis, Insights and Forecast - By Product Type
- 9.3.1. Biologics
- 9.3.2. Non-Biologics
- 9.4. Market Analysis, Insights and Forecast - By Route of Administration
- 9.4.1. Oral
- 9.4.2. Parenteral/Systemic
- 9.4.3. Topical
- 9.5. Market Analysis, Insights and Forecast - By Distribution Channel
- 9.5.1. Hospital Pharmacies
- 9.5.2. Retail Pharmacies
- 9.5.3. Online Pharmacies
- 9.6. Market Analysis, Insights and Forecast - By Country/Sub-region
- 9.6.1. Brazil
- 9.6.1.1. By Type
- 9.6.2. Mexico
- 9.6.2.1. By Type
- 9.6.3. Rest of Latin America
- 9.6.3.1. By Type
- 9.6.1. Brazil
10. Middle East & Africa Psoriasis Treatment Market Analysis, Insights and Forecast, 2021-2034
- 10.1. Market Analysis, Insights and Forecast - By Drug Class
- 10.1.1. TNF Inhibitors
- 10.1.2. Interleukins Inhibitors
- 10.1.3. Others
- 10.2. Market Analysis, Insights and Forecast - By Type
- 10.2.1. Plaque Psoriasis
- 10.2.2. Psoriatic Arthritis
- 10.2.3. Others
- 10.3. Market Analysis, Insights and Forecast - By Product Type
- 10.3.1. Biologics
- 10.3.2. Non-Biologics
- 10.4. Market Analysis, Insights and Forecast - By Route of Administration
- 10.4.1. Oral
- 10.4.2. Parenteral/Systemic
- 10.4.3. Topical
- 10.5. Market Analysis, Insights and Forecast - By Distribution Channel
- 10.5.1. Hospital Pharmacies
- 10.5.2. Retail Pharmacies
- 10.5.3. Online Pharmacies
- 10.6. Market Analysis, Insights and Forecast - By Country/Sub-region
- 10.6.1. GCC
- 10.6.1.1. By Type
- 10.6.2. South Africa
- 10.6.2.1. By Type
- 10.6.3. Rest of Middle East & Africa
- 10.6.3.1. By Type
- 10.6.1. GCC
11. Competitive Analysis
- 11.1. Global Market Share Analysis (2025)
- 11.2. Company Profiles
- 11.2.1. AbbVie Inc.
- 11.2.1.1. Overview
- 11.2.1.2. Products & Services
- 11.2.1.3. SWOT Analysis
- 11.2.1.4. Recent Developments
- 11.2.1.5. Strategies
- 11.2.1.6. Financials (Based on Availability)
- 11.2.2. Novartis AG
- 11.2.2.1. Overview
- 11.2.2.2. Products & Services
- 11.2.2.3. SWOT Analysis
- 11.2.2.4. Recent Developments
- 11.2.2.5. Strategies
- 11.2.2.6. Financials (Based on Availability)
- 11.2.3. Johnson & Johnson Services, Inc.
- 11.2.3.1. Overview
- 11.2.3.2. Products & Services
- 11.2.3.3. SWOT Analysis
- 11.2.3.4. Recent Developments
- 11.2.3.5. Strategies
- 11.2.3.6. Financials (Based on Availability)
- 11.2.4. Pfizer Inc.
- 11.2.4.1. Overview
- 11.2.4.2. Products & Services
- 11.2.4.3. SWOT Analysis
- 11.2.4.4. Recent Developments
- 11.2.4.5. Strategies
- 11.2.4.6. Financials (Based on Availability)
- 11.2.5. LEO Pharma A/S
- 11.2.5.1. Overview
- 11.2.5.2. Products & Services
- 11.2.5.3. SWOT Analysis
- 11.2.5.4. Recent Developments
- 11.2.5.5. Strategies
- 11.2.5.6. Financials (Based on Availability)
- 11.2.6. Merck & Co., Inc.
- 11.2.6.1. Overview
- 11.2.6.2. Products & Services
- 11.2.6.3. SWOT Analysis
- 11.2.6.4. Recent Developments
- 11.2.6.5. Strategies
- 11.2.6.6. Financials (Based on Availability)
- 11.2.7. Amgen Inc.
- 11.2.7.1. Overview
- 11.2.7.2. Products & Services
- 11.2.7.3. SWOT Analysis
- 11.2.7.4. Recent Developments
- 11.2.7.5. Strategies
- 11.2.7.6. Financials (Based on Availability)
- 11.2.8. Eli Lilly and Company
- 11.2.8.1. Overview
- 11.2.8.2. Products & Services
- 11.2.8.3. SWOT Analysis
- 11.2.8.4. Recent Developments
- 11.2.8.5. Strategies
- 11.2.8.6. Financials (Based on Availability)
- 11.2.9. Evelo Biosciences, Inc.
- 11.2.9.1. Overview
- 11.2.9.2. Products & Services
- 11.2.9.3. SWOT Analysis
- 11.2.9.4. Recent Developments
- 11.2.9.5. Strategies
- 11.2.9.6. Financials (Based on Availability)
- 11.2.10. UCB S.A.
- 11.2.10.1. Overview
- 11.2.10.2. Products & Services
- 11.2.10.3. SWOT Analysis
- 11.2.10.4. Recent Developments
- 11.2.10.5. Strategies
- 11.2.10.6. Financials (Based on Availability)
- 11.2.11. Sun Pharmaceutical Industries Ltd.
- 11.2.11.1. Overview
- 11.2.11.2. Products & Services
- 11.2.11.3. SWOT Analysis
- 11.2.11.4. Recent Developments
- 11.2.11.5. Strategies
- 11.2.11.6. Financials (Based on Availability)
- 11.2.1. AbbVie Inc.
List of Tables
- Table 1: Global Psoriasis Treatment Market Revenue (USD billion) Forecast, by Drug Class, 2021-2034
- Table 2: Global Psoriasis Treatment Market Revenue (USD billion) Forecast, by Type, 2021-2034
- Table 3: Global Psoriasis Treatment Market Revenue (USD billion) Forecast, by Product Type, 2021-2034
- Table 4: Global Psoriasis Treatment Market Revenue (USD billion) Forecast, by Route of Administration, 2021-2034
- Table 5: Global Psoriasis Treatment Market Revenue (USD billion) Forecast, by Distribution Channel, 2021-2034
- Table 6: Global Psoriasis Treatment Market Revenue (USD billion) Forecast, by Region, 2021-2034
- Table 7: North America Psoriasis Treatment Market Revenue (USD billion) Forecast, by Drug Class, 2021-2034
- Table 8: North America Psoriasis Treatment Market Revenue (USD billion) Forecast, by Type, 2021-2034
- Table 9: North America Psoriasis Treatment Market Revenue (USD billion) Forecast, by Product Type, 2021-2034
- Table 10: North America Psoriasis Treatment Market Revenue (USD billion) Forecast, by Route of Administration, 2021-2034
- Table 11: North America Psoriasis Treatment Market Revenue (USD billion) Forecast, by Distribution Channel, 2021-2034
- Table 12: North America Psoriasis Treatment Market Revenue (USD billion) Forecast, By Country, 2021-2034
- Table 13: U.S. Psoriasis Treatment Market Revenue (USD billion) Forecast, by Type, 2021-2034
- Table 14: Canada Psoriasis Treatment Market Revenue (USD billion) Forecast, by Type, 2021-2034
- Table 15: Europe Psoriasis Treatment Market Revenue (USD billion) Forecast, by Drug Class, 2021-2034
- Table 16: Europe Psoriasis Treatment Market Revenue (USD billion) Forecast, by Type, 2021-2034
- Table 17: Europe Psoriasis Treatment Market Revenue (USD billion) Forecast, by Product Type, 2021-2034
- Table 18: Europe Psoriasis Treatment Market Revenue (USD billion) Forecast, by Route of Administration, 2021-2034
- Table 19: Europe Psoriasis Treatment Market Revenue (USD billion) Forecast, by Distribution Channel, 2021-2034
- Table 20: Europe Psoriasis Treatment Market Revenue (USD billion) Forecast, By Country/ Sub-region, 2021-2034
- Table 21: U.K. Psoriasis Treatment Market Revenue (USD billion) Forecast, by Type, 2021-2034
- Table 22: Germany Psoriasis Treatment Market Revenue (USD billion) Forecast, by Type, 2021-2034
- Table 23: France Psoriasis Treatment Market Revenue (USD billion) Forecast, by Type, 2021-2034
- Table 24: Italy Psoriasis Treatment Market Revenue (USD billion) Forecast, by Type, 2021-2034
- Table 25: Spain Psoriasis Treatment Market Revenue (USD billion) Forecast, by Type, 2021-2034
- Table 26: Scandinavia Psoriasis Treatment Market Revenue (USD billion) Forecast, by Type, 2021-2034
- Table 27: Rest of Europe Psoriasis Treatment Market Revenue (USD billion) Forecast, by Type, 2021-2034
- Table 28: Asia Pacific Psoriasis Treatment Market Revenue (USD billion) Forecast, by Drug Class, 2021-2034
- Table 29: Asia Pacific Psoriasis Treatment Market Revenue (USD billion) Forecast, by Type, 2021-2034
- Table 30: Asia Pacific Psoriasis Treatment Market Revenue (USD billion) Forecast, by Product Type, 2021-2034
- Table 31: Asia Pacific Psoriasis Treatment Market Revenue (USD billion) Forecast, by Route of Administration, 2021-2034
- Table 32: Asia Pacific Psoriasis Treatment Market Revenue (USD billion) Forecast, by Distribution Channel, 2021-2034
- Table 33: Asia Pacific Psoriasis Treatment Market Revenue (USD billion) Forecast, By Country/ Sub-region, 2021-2034
- Table 34: China Psoriasis Treatment Market Revenue (USD billion) Forecast, by Type, 2021-2034
- Table 35: India Psoriasis Treatment Market Revenue (USD billion) Forecast, by Type, 2021-2034
- Table 36: Japan Psoriasis Treatment Market Revenue (USD billion) Forecast, by Type, 2021-2034
- Table 37: Australia & New Zealand Psoriasis Treatment Market Revenue (USD billion) Forecast, by Type, 2021-2034
- Table 38: Rest of Asia Pacific Psoriasis Treatment Market Revenue (USD billion) Forecast, by Type, 2021-2034
- Table 39: Latin America Psoriasis Treatment Market Revenue (USD billion) Forecast, by Drug Class, 2021-2034
- Table 40: Latin America Psoriasis Treatment Market Revenue (USD billion) Forecast, by Type, 2021-2034
- Table 41: Latin America Psoriasis Treatment Market Revenue (USD billion) Forecast, by Product Type, 2021-2034
- Table 42: Latin America Psoriasis Treatment Market Revenue (USD billion) Forecast, by Route of Administration, 2021-2034
- Table 43: Latin America Psoriasis Treatment Market Revenue (USD billion) Forecast, by Distribution Channel, 2021-2034
- Table 44: Latin America Psoriasis Treatment Market Revenue (USD billion) Forecast, By Country/ Sub-region, 2021-2034
- Table 45: Brazil Psoriasis Treatment Market Revenue (USD billion) Forecast, by Type, 2021-2034
- Table 46: Mexico Psoriasis Treatment Market Revenue (USD billion) Forecast, by Type, 2021-2034
- Table 47: Rest of Latin America Psoriasis Treatment Market Revenue (USD billion) Forecast, by Type, 2021-2034
- Table 48: Middle East & Africa Psoriasis Treatment Market Revenue (USD billion) Forecast, by Drug Class, 2021-2034
- Table 49: Middle East & Africa Psoriasis Treatment Market Revenue (USD billion) Forecast, by Type, 2021-2034
- Table 50: Middle East & Africa Psoriasis Treatment Market Revenue (USD billion) Forecast, by Product Type, 2021-2034
- Table 51: Middle East & Africa Psoriasis Treatment Market Revenue (USD billion) Forecast, by Route of Administration, 2021-2034
- Table 52: Middle East & Africa Psoriasis Treatment Market Revenue (USD billion) Forecast, by Distribution Channel, 2021-2034
- Table 53: Middle East & Africa Psoriasis Treatment Market Revenue (USD billion) Forecast, By Country/ Sub-region, 2021-2034
- Table 54: GCC Psoriasis Treatment Market Revenue (USD billion) Forecast, by Type, 2021-2034
- Table 55: South Africa Psoriasis Treatment Market Revenue (USD billion) Forecast, by Type, 2021-2034
- Table 56: Rest of Middle East & Africa Psoriasis Treatment Market Revenue (USD billion) Forecast, by Type, 2021-2034
List of Figures
- Figure 1: Global Psoriasis Treatment Market Revenue Breakdown (USD billion, %) by Region, 2025 & 2034
- Figure 2: Global Psoriasis Treatment Market Value Share (%), by Drug Class, 2025 & 2034
- Figure 3: Global Psoriasis Treatment Market Value Share (%), by Type, 2025 & 2034
- Figure 4: Global Psoriasis Treatment Market Value Share (%), by Product Type, 2025 & 2034
- Figure 5: Global Psoriasis Treatment Market Value Share (%), by Route of Administration, 2025 & 2034
- Figure 6: Global Psoriasis Treatment Market Value Share (%), by Distribution Channel, 2025 & 2034
- Figure 7: Global Psoriasis Treatment Market Value (USD billion), by Region, 2025 & 2034
- Figure 8: North America Psoriasis Treatment Market Value (USD billion), by Drug Class, 2025 & 2034
- Figure 9: North America Psoriasis Treatment Market Value Share (%), by Drug Class, 2025
- Figure 10: North America Psoriasis Treatment Market Value (USD billion), by Type, 2025 & 2034
- Figure 11: North America Psoriasis Treatment Market Value Share (%), by Type, 2025
- Figure 12: North America Psoriasis Treatment Market Value (USD billion), by Product Type, 2025 & 2034
- Figure 13: North America Psoriasis Treatment Market Value Share (%), by Product Type, 2025
- Figure 14: North America Psoriasis Treatment Market Value (USD billion), by Route of Administration, 2025 & 2034
- Figure 15: North America Psoriasis Treatment Market Value Share (%), by Route of Administration, 2025
- Figure 16: North America Psoriasis Treatment Market Value (USD billion), by Distribution Channel, 2025 & 2034
- Figure 17: North America Psoriasis Treatment Market Value Share (%), by Distribution Channel, 2025
- Figure 18: North America Psoriasis Treatment Market Value (USD billion), By Country, 2025 & 2034
- Figure 19: North America Psoriasis Treatment Market Value Share (%), By Country, 2025
- Figure 20: Europe Psoriasis Treatment Market Value (USD billion), by Drug Class, 2025 & 2034
- Figure 21: Europe Psoriasis Treatment Market Value Share (%), by Drug Class, 2025
- Figure 22: Europe Psoriasis Treatment Market Value (USD billion), by Type, 2025 & 2034
- Figure 23: Europe Psoriasis Treatment Market Value Share (%), by Type, 2025
- Figure 24: Europe Psoriasis Treatment Market Value (USD billion), by Product Type, 2025 & 2034
- Figure 25: Europe Psoriasis Treatment Market Value Share (%), by Product Type, 2025
- Figure 26: Europe Psoriasis Treatment Market Value (USD billion), by Route of Administration, 2025 & 2034
- Figure 27: Europe Psoriasis Treatment Market Value Share (%), by Route of Administration, 2025
- Figure 28: Europe Psoriasis Treatment Market Value (USD billion), by Distribution Channel, 2025 & 2034
- Figure 29: Europe Psoriasis Treatment Market Value Share (%), by Distribution Channel, 2025
- Figure 30: Europe Psoriasis Treatment Market Value (USD billion), By Country/ Sub-region, 2025 & 2034
- Figure 31: Europe Psoriasis Treatment Market Value Share (%), By Country/ Sub-region, 2025
- Figure 32: Asia Pacific Psoriasis Treatment Market Value (USD billion), by Drug Class, 2025 & 2034
- Figure 33: Asia Pacific Psoriasis Treatment Market Value Share (%), by Drug Class, 2025
- Figure 34: Asia Pacific Psoriasis Treatment Market Value (USD billion), by Type, 2025 & 2034
- Figure 35: Asia Pacific Psoriasis Treatment Market Value Share (%), by Type, 2025
- Figure 36: Asia Pacific Psoriasis Treatment Market Value (USD billion), by Product Type, 2025 & 2034
- Figure 37: Asia Pacific Psoriasis Treatment Market Value Share (%), by Product Type, 2025
- Figure 38: Asia Pacific Psoriasis Treatment Market Value (USD billion), by Route of Administration, 2025 & 2034
- Figure 39: Asia Pacific Psoriasis Treatment Market Value Share (%), by Route of Administration, 2025
- Figure 40: Asia Pacific Psoriasis Treatment Market Value (USD billion), by Distribution Channel, 2025 & 2034
- Figure 41: Asia Pacific Psoriasis Treatment Market Value Share (%), by Distribution Channel, 2025
- Figure 42: Asia Pacific Psoriasis Treatment Market Value (USD billion), By Country/ Sub-region, 2025 & 2034
- Figure 43: Asia Pacific Psoriasis Treatment Market Value Share (%), By Country/ Sub-region, 2025
- Figure 44: Latin America Psoriasis Treatment Market Value (USD billion), by Drug Class, 2025 & 2034
- Figure 45: Latin America Psoriasis Treatment Market Value Share (%), by Drug Class, 2025
- Figure 46: Latin America Psoriasis Treatment Market Value (USD billion), by Type, 2025 & 2034
- Figure 47: Latin America Psoriasis Treatment Market Value Share (%), by Type, 2025
- Figure 48: Latin America Psoriasis Treatment Market Value (USD billion), by Product Type, 2025 & 2034
- Figure 49: Latin America Psoriasis Treatment Market Value Share (%), by Product Type, 2025
- Figure 50: Latin America Psoriasis Treatment Market Value (USD billion), by Route of Administration, 2025 & 2034
- Figure 51: Latin America Psoriasis Treatment Market Value Share (%), by Route of Administration, 2025
- Figure 52: Latin America Psoriasis Treatment Market Value (USD billion), by Distribution Channel, 2025 & 2034
- Figure 53: Latin America Psoriasis Treatment Market Value Share (%), by Distribution Channel, 2025
- Figure 54: Latin America Psoriasis Treatment Market Value (USD billion), By Country/ Sub-region, 2025 & 2034
- Figure 55: Latin America Psoriasis Treatment Market Value Share (%), By Country/ Sub-region, 2025
- Figure 56: Middle East & Africa Psoriasis Treatment Market Value (USD billion), by Drug Class, 2025 & 2034
- Figure 57: Middle East & Africa Psoriasis Treatment Market Value Share (%), by Drug Class, 2025
- Figure 58: Middle East & Africa Psoriasis Treatment Market Value (USD billion), by Type, 2025 & 2034
- Figure 59: Middle East & Africa Psoriasis Treatment Market Value Share (%), by Type, 2025
- Figure 60: Middle East & Africa Psoriasis Treatment Market Value (USD billion), by Product Type, 2025 & 2034
- Figure 61: Middle East & Africa Psoriasis Treatment Market Value Share (%), by Product Type, 2025
- Figure 62: Middle East & Africa Psoriasis Treatment Market Value (USD billion), by Route of Administration, 2025 & 2034
- Figure 63: Middle East & Africa Psoriasis Treatment Market Value Share (%), by Route of Administration, 2025
- Figure 64: Middle East & Africa Psoriasis Treatment Market Value (USD billion), by Distribution Channel, 2025 & 2034
- Figure 65: Middle East & Africa Psoriasis Treatment Market Value Share (%), by Distribution Channel, 2025
- Figure 66: Middle East & Africa Psoriasis Treatment Market Value (USD billion), By Country/ Sub-region, 2025 & 2034
- Figure 67: Middle East & Africa Psoriasis Treatment Market Value Share (%), By Country/ Sub-region, 2025
- Figure 68: Global Psoriasis Treatment Market Share (%), By Company, 2025
